South Denver Cardiology
Back to Trials

GENETIC-AF

Short Description

Effectiveness trial of bucindolol and Toprol-XL for prevention of symptomatic AF

GENETIC-AF: A genotype-directed comparative effectiveness trial of bucindolol and Toprol-XL for prevention of symptomatic AF/AFL in patients with heart failure. The goal of this study is to demonstrate the superiority of pharmacogenetically targeted bucindolol compared to metoprolol for the prevention of symptomatic AF/AFL in a genotype-defined B1389Arg/Arg HFREF population at high risk of AF/AFL recurrence.

Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275

South Denver Cardiology
Latest posts by South Denver Cardiology (see all)

Recommend

  • This field is for validation purposes and should be left unchanged.
  • MM slash DD slash YYYY
  • What questions do you have regarding your bill?